Cardiovascular Risk Assessment in Patients with Bronchiectasis: Insights from the Canadian Bronchiectasis and NTM (CanBE-NTM) Registry

Extract Cardiovascular disease (CVD) is a major cause of morbidity and mortality in people with chronic respiratory disease. Although COPD is now included in cardiovascular risk tools, bronchiectasis remains under-recognized despite similar systemic inflammation, hypoxemia, and exacerbation burden. [1] Epidemiologic data, including a meta-analysis of over 22 000 people, confirm increased CVD incidence in those with bronchiectasis [2]. However, prior studies have been single-center, administrative, or outcome-focused rather than examining risk assessment. To our knowledge, this is the first national, registry-based evaluation of cardiovascular screening in bronchiectasis, providing new insight into investigation patterns and calculated risk across a Canadian cohort.